Sun Pharmaceutical Industries has published newspaper advertisements regarding the postal ballot process for appointing Ms. Satyavati Berera as an Independent Director. The company filed an intimation under Regulation 30 of SEBI regulations on April 8, 2026, confirming the publication of advertisements in Financial Express editions containing postal ballot and e-voting information.

Newspaper Advertisement Publication

The pharmaceutical company published advertisements in all editions of Financial Express (English) and Ahmedabad Edition of Financial Express (Gujarati) on April 8, 2026. The newspaper clippings have been attached as Annexure-A and are available on the company's website at www.sunpharma.com .

Updated E-Voting Timeline

The postal ballot notice reveals updated e-voting parameters for shareholder approval of Ms. Berera's appointment. The process includes specific timelines for remote voting and comprehensive shareholder communication.

Director Appointment Background

The appointment of Ms. Satyavati Berera comes as Ms. Rama Bijapurkar, the current Woman Independent Director, completes her five-year term on May 20, 2026. Ms. Bijapurkar has conveyed her unwillingness to seek reappointment due to personal reasons. Under SEBI Listing Regulations, the company must maintain at least one Woman Independent Director on its board at all times.

Professional Credentials and Board Memberships

Ms. Satyavati Berera brings extensive leadership experience from her tenure as Chief Operating Officer of PwC India, where she served for over 40 years before retiring in 2023. Her professional background includes serving as an Audit Partner from 1995 to 2005 and heading the consulting practice as Managing Partner for the northern region.

The 65-year-old chartered accountant, who qualified in 1984, currently holds directorships in three other listed companies:

Regulatory Compliance and Shareholder Communication

The Board of Directors has confirmed that Ms. Berera meets all independence criteria under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of SEBI Listing Regulations. The company has verified that she has no material pecuniary relationships, prior employment history, or conflicting interests with Sun Pharmaceutical Industries.

Shareholders can access the postal ballot notice on the company's website, stock exchange websites (BSE and NSE), and CDSL's e-voting platform. The company's Registrar and Transfer Agent, MUFG Intime India Private Limited, provides support for shareholders requiring assistance with the e-voting process.

Sun pharmaceutical Industries Ltd. executed a significant block trade on the National Stock Exchange (NSE), marking a notable institutional transaction in the pharmaceutical sector.

Transaction Details

The block trade involved substantial volume and value, demonstrating active institutional participation in the company's stock.

Market Significance

Block trades typically represent large-volume transactions executed outside regular market mechanisms, often involving institutional investors, mutual funds, or other bulk participants. These transactions are usually pre-negotiated between parties and executed at agreed prices.

The execution price of ₹1761.30 per share reflects the negotiated value for this particular transaction. Such trades provide liquidity for large shareholders while minimizing market impact that might occur through regular market transactions.

Transaction Context

The pharmaceutical sector continues to attract institutional interest, with companies like Sun Pharmaceutical Industries remaining active in block trade segments. These transactions often indicate portfolio adjustments by institutional investors or strategic stake changes by large shareholders.